Nano-trapping CXCL13 reduces regulatory B cells in tumor microenvironment and inhibits tumor growth

J Control Release. 2022 Mar:343:303-313. doi: 10.1016/j.jconrel.2022.01.039. Epub 2022 Jan 29.

Abstract

Interactions between different cell types in the tumor microenvironment (TME) affect tumor growth. Tumor-associated fibroblasts produce C-X-C motif chemokine ligand 13 (CXCL13) which recruits B cells to the TME. B-cells in the TME differentiate into regulatory B cells (Bregs) (IL-10+CD1d+CD5+CD138+CD19+). We highlight these Breg cells as a new important factor in the modulation of the immunosuppressive TME in different desmoplastic murine tumor models. In addition, CXCL13 also stimulates epithelial-mesenchymal transition (EMT) of the tumor cells. The tumorigenic roles of CXCL13 led us to explore an innovative anti-cancer strategy based on delivering plasmid DNA encoding a CXCL13 trap to reduce Bregs differentiation and normalize EMT, thereby suppressing tumor growth. CXCL13 trap suppressed tumor growth in pancreatic cancer, BRAF-mutant melanoma, and triple-negative breast cancer. In this study, following treatment, the affected tumor remained dormant resulting in prolonged progression-free survival of the host.

Keywords: C-X-C motif chemokine ligand 13; Desmoplastic tumor; Pancreatic cancer; Regulatory B cells; Tumor microenvironment; Tumor-associated fibroblasts.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • B-Lymphocytes, Regulatory* / metabolism
  • Cancer-Associated Fibroblasts*
  • Chemokine CXCL13 / genetics
  • Chemokine CXCL13 / metabolism
  • Humans
  • Mice
  • Pancreatic Neoplasms* / metabolism
  • Triple Negative Breast Neoplasms* / therapy
  • Tumor Microenvironment

Substances

  • CXCL13 protein, human
  • Chemokine CXCL13
  • Cxcl13 protein, mouse